Document Detail


Endocrinological, metabolic and clinical features of treatment with oral contraceptive formulation containing ethinylestradiol plus chlormadinone acetate in nonobese women with polycystic ovary syndrome.
MedLine Citation:
PMID:  20654753     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
BACKGROUND: Chlormadinone acetate (CMA) is a progestin compound similar to progesterone, with antiandrogenic properties. In healthy eumenorrheic women, it was demonstrated that the monophasic estroprogestin formulation containing CMA (2 mg) plus ethinyl estradiol (EE) (30 mcg) (EE30+CMA) is efficacious both in reducing hyperandrogenic symptoms, fat mass and in improving lipoprotein panel, without changes in insulin-glucose metabolism. These metabolic properties are important for women affected by polycystic ovary syndrome (PCOS) in whom there is a predisposition to insulin resistance. STUDY DESIGN: We studied whether in young nonobese women with PCOS (15 subjects, EE30+CMA-PCOS group) a six-cycle treatment with EE30+CMA can reduce androgen levels, androgen bioavailability and the score of hirsutism and acne, and modify glucose-insulin metabolism evaluated by the oral glucose tolerance test and the body composition evaluated by bio-impedenziometry. These parameters were evaluated before (first visit) and during the sixth cycle of EE30+CMA (second visit). All the results were compared with those of a matched-age-group of nonobese PCOS women (15 subjects, no OC-PCOS group) evaluated before (first visit) and after six menstrual cycles in which they did not use any drug or oral contraceptive (second visit). RESULTS: In the EE30+CMA-PCOS group women, androgen levels and bioavailability, hirsutism and acne score were significantly lower at the second than at the first visit, whereas they did not change in no OC-PCOS group. At the second visit, in both groups, glucose-insulin metabolism and body composition parameters were not affected. CONCLUSIONS: A six-cycle treatment with EE30+CMA is efficacious in nonobese PCOS women to improve hyperandrogenic symptoms, without negative interferences both on body composition and on insulin-glucose metabolism.
Authors:
Roberto Uras; Marisa Orrù; Fabiana Pani; Maria Francesca Marotto; Monica Pilloni; Stefano Guerriero; Rossella Etzi; Pierina Zedda; Roberto Sorge; Stefano Lello; Gian Benedetto Melis; Anna Maria Paoletti
Related Documents :
1559293 - Improvement in endocrine and ovarian function during dietary treatment of obese women w...
7875653 - Androgen-related effects on peripheral glucose metabolism in women with congenital adre...
20097783 - Comparison of radioimmunoprecipitation with luciferase immunoprecipitation for autoanti...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2010-03-01
Journal Detail:
Title:  Contraception     Volume:  82     ISSN:  1879-0518     ISO Abbreviation:  Contraception     Publication Date:  2010 Aug 
Date Detail:
Created Date:  2010-07-26     Completed Date:  2010-11-01     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  0234361     Medline TA:  Contraception     Country:  United States    
Other Details:
Languages:  eng     Pagination:  131-8     Citation Subset:  IM    
Copyright Information:
Copyright 2010 Elsevier Inc. All rights reserved.
Affiliation:
Department of Obstetrics and Gynaecology, University of Cagliari, 09124 Cagliari, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Acne Vulgaris / physiopathology
Androgens / blood
Anthropometry
Body Composition / physiology
Chlormadinone Acetate / administration & dosage,  pharmacology*,  therapeutic use
Contraceptives, Oral, Combined / administration & dosage,  pharmacology*,  therapeutic use
Electric Impedance
Ethinyl Estradiol / administration & dosage,  pharmacology*,  therapeutic use
Female
Glucose / analysis,  metabolism*
Glucose Tolerance Test
Hirsutism / physiopathology
Humans
Insulin / analysis,  metabolism*
Polycystic Ovary Syndrome / drug therapy*,  metabolism
Young Adult
Chemical
Reg. No./Substance:
0/Androgens; 0/Contraceptives, Oral, Combined; 11061-68-0/Insulin; 302-22-7/Chlormadinone Acetate; 50-99-7/Glucose; 57-63-6/Ethinyl Estradiol

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  The missing IUD.
Next Document:  Effect of oral contraceptive containing ethinyl estradiol combined with drospirenone vs. desogestrel...